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Patent production is a prerequisite for
successful exit of a biopharmaceutical
company
Chikako Saotome, saotome.chikako.2z@kyoto-u.ac.jp, Yurie Nakaya and Seiji Abe
Patents are especially important for the business of drug discovery; however, their importance for
biopharmaceutical companies has not been revealed quantitatively yet. To examine the correlation
between patents and long-term business outcome of biopharmaceutical companies we analyze annual
number of patent families and business conditions of 123 public-listed biopharmaceutical companies
established from 1990 to 1995 in the USA. Our results show the number of patent families per year
correlates well with the business condition: average of the bankruptcy group is significantly smaller than
those of the continuing and the merger and acquisitions (M&A) groups. In the M&A by big pharma
group, the acquisition cost correlates with the number of annual patent families. However, patentability
and strategy of foreign patent application are not different among the groups. Therefore, the
productivity of invention is the key factor for success of biopharmaceutical companies.
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Biopharmaceutical companies have an impor-
tant role in open innovation in drug discovery.
Although intellectual property is important for
drug development, there are few studies
quantitatively analyzing patents as a success
factor of biopharmaceutical companies. Parida
et al. investigated the numbers of granted
patents in the USA, candidates in Phase III and
products on the market from 59 American bio-
pharmaceutical companies established between
1992 and 2002, and concluded that there is no
correlation between the number of patents and
production of drugs or drug candidates in these
biotech companies [1]. Deeds et al. reported that
factors correlating with the amount of capital at
the initial public offering (IPO) are location of the406 www.drugdiscoverytoday.comcompany, the number of products in develop-
ment and the times of citation on works by
scientists of the company and not the number of
patents [2]. Lichtenthaler, by contrast, classified
136 European firms into low-, medium- and
high-tech firms, and showed that in high-tech
firms the return on sales strongly and positively
correlates with patent portfolio size [3]. Because
a lot of money and time are spent on devel-
opment of pharmaceutical products, successful
biopharmaceutical companies are supposedly
more eager to protect their research results as
intellectual property to survive in their business.
We, therefore, hypothesize that innovative bio-
tech companies file patents more actively, which
ultimately increases their value. Here, we take
into account several factors to examine theimportance of patents quantitatively in success
of biopharmaceutical companies. First, we in-
vestigate not only granted US patents but also all
patent applications of each company. Next, to
eliminate time factor such as time lag between
application and grant of patents and years in
business, we examine the annual number of
patent application to quantitate research efforts
of each company. Furthermore, we do not think
the amount of IPO an appropriate measure for
evaluation for biopharmaceutical companies,
because almost no product is marketed at the
time of IPO. We, therefore, analyze patent fam-
ilies [a set of patent application(s) from single
invention in the USA and abroad] of 123 public-
listed biopharmaceutical companies established
from 1990 to 1995 in the USA to examine the1359-6446/ 2015 Elsevier Ltd. All rights reserved.
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FIGURE 1
Average number of annual patent families.
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maceutical company success.
Identification and classification of
biopharmaceutical companies for analysis
We searched biopharmaceutical companies in
the USA through EDGAR, an online database of
the US Securities and Exchange Commission, in
five sections with sic codes 2833 (medicinal
chemicals and botanical products), 2834 (phar-
maceutical preparations), 2835 (in vitro and in
vivo diagnostic substances), 2836 (biological
products) and 8731 (services-commercial phys-
ical and biological research), and picked up all
start-up companies established from 1990 to
1995 for drug discovery in the USA (see Table S1
in Supplementary Material online). We then ex-
amined the business state at September 2012 of
these 123 companies from their annual reports
(form 10-K) from EDGAR and classified their
business conditions according to the ‘exit’ (i.e.
bankruptcy, continuing and M&A). Forty-eight
companies (39%) continue their business by
themselves for about 20 years (the continuing
group). Twenty-seven companies (22%) quitted
their business or delisted (the bankruptcy
group). The remaining 48 companies belong to
the M&A group, which is further divided into
two. Eighteen companies (15%) were acquired
by pharmaceutical companies (the M&A by big
pharma group) and 30 companies (24%) were
acquired by other biopharmaceutical companies
established after 1976 (the M&A by biotech
group). For these M&A groups, we checked the
M&A cost of each company by press release or
newspapers.
Annual patent family number and exit
We searched patent families of each company as
of September 2012 through the Thomson Reu-
ters’ commercial database: the Derwent Inno-
vations Index. We first counted the total number
of patent families of each company by this time.
The average and median values of annual
numbers of patent families of 123 biopharma-
ceutical companies are 4.9 and 2.2, respectively
(Fig. 1). Among them, only six companies (5%)
had no patent family. The bankruptcy group
showed the average and median values of 1.6
and 1.4, respectively, and their average value is
significantly smaller than those of the continuing
and the M&A groups (P < 0.01). Among the 27
bankruptcy companies, seven companies (26%)
had less than 1.0 annual patent families and 12
(44%) companies had between 1.0 and 2.0 with
only eight companies (30%) with more than 2.1.
The average and median values of the con-
tinuing group are 3.5 and 2.3, respectively.Among the 48 continuing companies, 15 com-
panies (31%) had less than 1.0 annual patent
families, seven companies (15%) between 1.0
and 2.0 and 26 companies (54%) more than 2.1
with 13 companies (27%) producing more than
4.9. The average and median values of the M&A
group are 8.1 and 3.6, respectively. Among the
M&A group, the M&A by big pharma group has
higher average (13.9) and median (4.4) values
than those of the M&A by biotech group (4.6 and
2.4, respectively), and the average value of the
M&A by big pharma is significantly higher than
those of the bankruptcy group (P < 0.05).
Among the 30 M&A by biotech companies, four
companies (13%) had less than 1.0 annual patent
families, ten companies (33%) between 1.0 and
2.0 and 16 companies (53%) more than 2.1 with
eight companies (27%) producing more than 4.9.
In the 18 M&A by big pharma companies, only
three companies (17%) had less than 1.0 annual
patent families, 13 companies (72%) more than
2.1 and eight companies (44%) producing more
than 4.9. Companies producing the highest and
the second-highest number of annual patent
families are Millennium Pharmaceuticals (81.5)
and Human Genome Science (60.9), respectively,
both of which belong to the M&A by big pharma
group.
Patent family analysis
We next analyzed in more detail the patent
families in terms of the quality of patent and
foreign patent application (Table 1). The ratio of
granted patent in any country, which we eval-
uated as a measure of the quality of invention,
ranged from 60% to 70% and, although the
values of the M&A by biotech group are higher
than those of the bankruptcy group and the
continuing group (P < 0.05 and P < 0.01, re-spectively), the difference between their per-
centage values was not big. We next analyzed
their foreign patent applications. Because Eur-
ope, USA and Japan occupy about 70% of the
drug market in the world according to report by
IMS Health http://www.imshealth.com/files/
web/Corporate/News/Top-Line%20Market%20-
Data/Global%20Prescription%20Sales%20
Information5%20World%20figures%20by%
20Region%202015-2019.pdf, we examined the
percentage of their Patent Cooperation Treaty
(PCT) application to the World Intellectual
Property Organization (WIPO) and the percent-
age and number of applications to European, US
and Japanese patent offices in addition to WIPO
as the ‘tripod patent family’. These analyses have
revealed that there is no difference in the per-
centage of the PCT applications, EU applications
and the tripod applications and the average
number of filed countries. However, the annual
numbers of tripod patent families, either total or
granted, of the M&A group is significantly more
than those of the other two groups. These
findings indicate that all the groups adopted the
same patent policy but the number of patents
that matter was different among the groups.
Correlation between patent number and
the M&A cost
We finally analyzed the annual number of patent
families and the acquisition cost of each com-
pany in the M&A groups (Figs 2,3). We identified
acquisition costs of 28 out of 30 companies in
the M&A by biotech group, and found that the
average cost of acquisition of these companies
was US$477 million. The analysis found no cor-
relation between the acquisition cost and the
annual patent families number (r = 0.0). We
identified all acquisition costs in the M&A by bigwww.drugdiscoverytoday.com 407
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TABLE 1
Analysis of patent family
Bankruptcy
(n = 27)
Continuing
(n = 48)
M&A
(n = 48)
M&A by big
pharma (n = 18)
M&A by biotech
(n = 30)
Granted patent (%)a 59.7  28.7 53.7  14.3 70.6  17.8c 64.3  18.3d 74.6  16.6e,c
PCT (%)a 82.3  16.7 83.7  14.4 73.7  23.8d 78.7  15.0 70.6  27.7d
EU (%)a 57.9  15.6 60.1  17.7 56.0  18.7 57.0  15.0 55.4  21.0
Country numbera 3.7  1.6 3.8  1.2 3.7  1.4 3.8  1.3 3.6  1.4
Tripod patent (%)a 35.9  21.8 42.5  16.6 38.7  15.9 38.4  12.4 38.9  18.0
Annual tripod patent families 0.6  0.5 1.3  1.6b 2.4  3.2b,d 3.8  4.5b,d 1.6  1.8b
Annual tripod patent families with granted patent 0.5  0.4 0.9  1.0b 2.0  2.4b,c 3.0  3.3b,d 1.4  1.6b
Annual tripod patent families with more
than five countries
0.4  0.3 0.8  0.9b 1.2  1.3b 1.8  1.7b,d 0.8  0.9e
Annual tripod patent families with more
than ten countries
0.2  0.2 0.3  0.3 0.4  0.7e 0.6  0.8e 0.3  0.6
a Calculated without companies with no patent family (bankruptcy: 1; continuing: 4; M&A by biotech: 1).
b Significance level is less than 1% compared to the bankruptcy group.
c Significance level is less than 1% compared to the continuing group.
d Significance level is less than 5% compared to the continuing group.
e Significance level is less than 5% compared to the bankruptcy group.
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FIGURE 2
Acquisition cost versus annual patent families number in the M&A by biotech group.
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FIGURE 3
Acquisition cost versus annual patent families number in the M&A by big pharma group.
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was more expensive (US$1283 million) than that
of M&A by biotech group. In contrast to the M&A
by biotech group, modest correlation (r = 0.80)
was found between the cost and the annual
number of patent families in the M&A by big
pharma group. These results suggest that
pharmaceutical companies hold high value on
the intellectual property of a biopharmaceutical
company in their evaluation. Both groups show
no correlation between acquisition cost and
acquisition year (data not shown).
Discussion
Here we examined the importance of intellectual
property management for biopharmaceutical
companies by investigating all patent families
(inventions) of 123 public-listed biopharmaceu-
tical companies established about 20 years ago.
Our results show that the number of patent
families per year correlates well with the busi-
ness condition of biopharmaceutical companies
and the value of M&A by big pharma, although
patentability and strategy of foreign patent ap-
plication are not different among the groups.
Therefore, the productivity of invention is the
key factor for success of biopharmaceutical
companies.
A question is why the annual patent families
number correlates with the business condition of
biopharmaceutical companies in our study de-
spite previous reports that the number of
patents was correlated neither with production
of drug [1] nor the value at the IPO [2]. First, even
the bankruptcy companies among the bio-
pharmaceutical companies in our analysis had
had value for investors at the time of IPO.
Such value was probably based on location
Drug Discovery Today  Volume 21, Number 3 March 2016 PERSPECTIVE
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development and the times of citation on works
by scientists of the company and not the number
of patents as reported by Deeds et al. [2].
However, they had not developed drugs or
technologies of their own since then and failed
to make an invention. As a consequence, they
could have lost competitiveness and the value
for investors and pharmaceutical companies,
and they went bankrupt because they failed to
get funding for drug development. By contrast,
innovative biopharmaceutical companies ap-
parently have more drugs and technologies of
their own. They, therefore, became the target for
acquisition by pharmaceutical companies that
want to expand their drug pipelines or introduce
new technologies. Stuart et al. investigated al-
liance activities of biotech companies with uni-
versities (upstream alliances) as well as
pharmaceutical companies (downstream alli-
ances) and found that many young biotech-
nology firms act as intermediaries in such
tripartite alliance chains but the positive rela-
tionship between in-licenses from upstream al-
liance and revenue generation from
downstream alliance attenuates in matured
biotech companies [4]. Their results support the
importance for biopharmaceutical companies to
conduct original research in house. Pharma-
ceutical companies could place more value on
actual drugs or drug candidates and/or new
technology to generate them filed in patents
than biotech companies, because of correlation
between annual patent families number and
acquisition cost in the M&A by big pharma.
Furthermore, having their own patents reduces
the risk for patent infringement or licenses.
Therefore, patent production is a prerequisite for
being continuing or bought by M&A of bio-
pharmaceutical companies. Even though the
annual patent families number of the M&A by
biotech group is significantly more than that of
the bankruptcy and the continuing groups, it hasno correlation with M&A cost. There could be
difference of aim and evaluation for M&A be-
tween big pharma and biotech companies.
Which factor of inventiveness determines the
outcome of biopharmaceutical companies that
have only limited resource at their beginning?
Our research showed that companies producing
the highest and the second-highest number of
annual patent families are Millennium Pharma-
ceuticals and Human Genome Science. They
conducted research on identification of new
causative genes in various human diseases for
development of new drugs. We suggest that
conducting drug discovery research based on
new technology from an early phase of its de-
velopment results in many inventions. Active
patent application policy combined with such
research activity is also important for producing
many inventions.
Concluding remarks
Our results clearly show that the continuing
group and M&A groups have filed significantly
more patents per year than the bankrupted
biopharmaceutical companies. M&A companies
filed plenty of patents each year, and their ac-
quisition cost increased as they filed more
patents. M&A groups also had a slightly higher
ratio of granted patents. Therefore, capability of
making an invention is crucial for biotech
companies. Source of creation of invention and
success factor of biopharmaceutical companies
are factors that will be identified in future by
analysis of a claim of patent application, business
model, number of products and alliance.
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